

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33

Supplementary data

TFEB promotes GK-induced ferroptosis via TRIM25 mediated GPX4 lysosomal degradation in EGFR wide-type lung adenocarcinoma

Hao-Jie Wang^{1,2,3#}, Ling-feng Dong^{1,2#}, Li-Li Ding³, Xiu-Yuan Miao^{1,2}, Yu-Wen Zhang^{1,2}, Li-Ping Zhao^{1,2}, Li-Hua Yu^{1,2}, Zhen-Rong Guan^{1,2}, Ya-Ping Jiang^{1,2}, Xiao-Qi Tang^{1,2}, Ya-Xin Yan^{1,2}, Jian-Shu Lou^{1,2,*}


¹School of Pharmacy, Hangzhou Normal University, Hangzhou, Zhejiang 311121, China;

²Key Laboratory of Elemene Class Anti-Cancer Chinese Medicines; Engineering Laboratory of Development and Application of Traditional Chinese Medicines; Collaborative Innovation Center of Traditional Chinese Medicines of Zhejiang Province, Hangzhou Normal University, Hangzhou, Zhejiang 311121, China.

³Shanghai Key Laboratory of Complex Prescription and MOE Key Laboratory for Standardization of Chinese Medicines, Institute of Chinese Materia Medica, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China

These authors contributed equally to this work

**Correspondence: Prof. Jian-Shu Lou, E-mail: jlouab@connect.ust.hk*



35

36 **Supplementary Figure S1 TFEB acts as a cancer suppress gene in LUAD.**37 **(A)** Pan-cancer analysis of TFEB expression across various tumor types38 compared to normal tissues, using data from the TCGA database. **(B)** Pan-

39 cancer analysis of TFEB expression in LUAD tissues compared to normal

40 tissues, integrating data from the TCGA and GTEx databases. **(C, D)** Kaplan-


41 Meier survival analysis of LUAD samples based on TFEB expression levels

42 using the TCGA and GTEx databases (C) and the KM Plotter database (D). **(E)**

43 Functional state analysis of TFEB in LUAD cells from the CancerSEA database.

44 **(F)** TFEB expression analysis in LUAD tissues at different stages and in normal45 lung tissues, performed with UALCAN. * $P < 0.05$, **** $P < 0.001$.

46




47

48 **Supplementary Figure S2 The changes of TFEB related protein and the**
 49 **binding of TFEB and 14-3-3 in GK treated LUAD cells.**

50 **(A)** The semi-quantitative analysis of 14-3-3, TFEB, P-TFEB(Ser122) and P-
 51 TFEB(Ser211) expression in figure 1D. $n = 3$, $*P < 0.05$, $**P < 0.01$. **(B)** LUAD
 52 cells were treated with GK for 6, 12, 24, and 48 h. After treatment, the cells
 53 were collected, lysed, and immunoprecipitated using an anti-TFEB antibody.
 54 The precipitated proteins or cell lysates were subjected to immunoblotting with
 55 anti-14-3-3 and anti-TFEB antibodies to assess protein interactions and
 56 expression changes.

57




58

59 **Supplementary Figure S3 GK activates TFEB in LCC cells.**

60 **(A)** LCC cells NCI-H460 were treated with GK for 6, 12, 24, and 48 h. Western
61 blotting was conducted to analyze the protein levels of TFEB, p-TFEB (Ser122),
62 p-TFEB (Ser211), and 14-3-3. **(B)** LCC cells NCI-H460 were treated as in (A).
63 After treatment, the cells were collected, lysed, and immunoprecipitated using
64 an anti-TFEB antibody. The precipitated proteins or cell lysates were subjected
65 to immunoblotting with anti-14-3-3 and anti-TFEB antibodies to assess protein
66 interactions and expression changes. **(C)** LCC cells NCI-H460 were treated
67 with GK for 24 h, and the nuclear translocation of TFEB was observed by
68 immunofluorescence (upper panel). Scale bar = 20 μ m. Co-localization
69 coefficients were calculated by measuring the co-localizing pixels between
70 TFEB (green fluorescence) and DAPI (blue fluorescence) relative to the total
71 number of pixels for the nuclei (DAPI channel) (lower panel). $n = 4$, $**P < 0.01$.
72 **(D)** The cytoplasmic and nuclear protein of LCC cells NCI-H460 were extracted
73 after 24 h GK treatment. The protein expression of TFEB in each fraction were
74 investigated by western blot. β -actin served as a marker of cytoplasm, while
75 Lamin A served as a marker of nucleus (left panel). The semi-quantitative
76 analysis of TFEB protein (right panel). $n = 3$, $*P < 0.05$, $**P < 0.01$.

77




78

79 **Supplementary Figure S4 GK activates lysosome in LCC cells and**
 80 **decreases lysosome pH in LUAD cells.**

81 **(A)** LCC cells NCI-H460 were treated with GK (15 μ M) for 24 h. Following
 82 treatment, cells were harvested, and mRNA was extracted and subsequently
 83 reverse transcribed into cDNA. The mRNA level of CTSD, ATP6V0D1 and
 84 MCOLN1 were detected by qPCR. $n = 3$, $**P < 0.01$, $***P < 0.001$, $****P <$
 85 0.0001 . **(B)** LCC cells NCI-H460 were treated with GK for 24, 48 h, then labeled
 86 with LysoTracker™ Red DND-99 (50 nM) for 30 min. Fluorescence intensity of
 87 10,000 cells per sample was measured by flow cytometry. The fluorescence
 88 intensity of the cells was displayed in histograms. **(C)** The relative changes in
 89 mean fluorescence intensity (MFI) for each treatment group compared to the
 90 control group, calculated from (B). $n = 3$, $****P < 0.0001$. **(D)** LCC cells NCI-
 91 H460 were treated same as in (B), then stained with Magic Red for 30 min. The
 92 level of cathepsin B was analyzed by flow cytometry. Fluorescence intensity of
 93 10,000 cells per sample was analyzed. The fluorescence intensity of the cells

94 was displayed in histograms (left panel), and the relative changes in mean
 95 fluorescence intensity (MFI) compared to the control was quantified (right
 96 panel). $n = 3$, **** $P < 0.0001$. (E) A549 WT cells and TFEB knockout cells
 97 (TFEB^{-/-}-2, TFEB^{-/-}-4) were treated with GK for 24 h, then stained with
 98 LysoSensor™ Yellow/Blue DND-160 (1 μ M) for 5 min. The blue fluorescence
 99 and yellow fluorescence were detected using a Multiskan™ FC Microplate
 100 Photometer. The ratio of the intensity of yellow fluorescence relative to blue
 101 fluorescence was calculated to indicate the pH in the lysosome. $n = 4$, ** $P <$
 102 0.01, **** $P < 0.0001$. (F) SPC-A-1 cells were treated with GK and tested the
 103 same as in (E), the ratio of the intensity of yellow fluorescence relative to blue
 104 fluorescence was calculated. $n = 4$, ** $P < 0.01$.
 105




106

SPC-A-1

107 **Supplementary Figure S5 GK promoted GPX4 lysosomal degradation and**
 108 **the binding of GPX4 with TRIM25 in SPC-A-1 cells.**

109 (A) SPC-A-1 cells were treated with GK (15 μ M) for 24, 48 h. The cells were

110 harvested, and mRNA was extracted and reverse transcribed into cDNA. The
111 mRNA level of GPX4 was investigated by qPCR. $n = 3$. **(B)** A549 cells were
112 treated with CHX (1 $\mu\text{g}/\text{mL}$), CHX+GK (1 $\mu\text{g}/\text{mL}$ + 15 μM) for 6, 12, 24 h, the
113 protein expression of GPX4 was observed by western blot. **(C)** SPC-A-1 cells
114 were transfected with 3 \times Flag-GPX4 and HA-Ub-K48, then treated with GK for
115 12, 24, 48 h, cells were collected and lysed. 100 μg of the cell lysates of each
116 sample were subdivided and used as input control. The left cell lysates were
117 subjected to immunoprecipitation via protein G beads and Flag antibody. The
118 expression of K48-linked polyubiquitin, flag-GPX4, TRIM25 and LAMP2A in
119 immunoprecipitants and input were investigated by western blot. **(D)** SPC-A-1
120 cells and TFEB knockout cells were treated GK (15 μM) for 12 h. The co-
121 localization of GPX4 and TRIM25 was observed by immunofluorescence assay.
122 Scale bar = 20 μM .




123

124 **Supplementary Figure S6 Semi-quantitative analysis of protein changes**
 125 **in GK induced degradation of GPX4.**

126 **(A)** Generation of TFEB knockout cells using the CRISPR-Cas9 system. Single
 127 cells were seeded in 96-well plates and cultured for 2–3 weeks to form single-
 128 cell colonies. Two monoclonal knockout (KO) cell lines with stable TFEB
 129 knockout were selected (A549 TFEB^{-/-}-2 and A549 TFEB^{-/-}-4). Western blot
 130 analysis of TFEB expression in A549 cells and TFEB knockout A549 cells. **(B)**
 131 A549 cells were treated with GK in the presence or absence of MG132, the


132 expression of GPX4 were analyzed by western blot. **(C, D)** Semiquantitative
 133 analysis of GPX4 expression from Figure 4B (C) and Figure 4C (D). $n = 3$. $*P < 0.05$, $**P < 0.01$, $***P < 0.001$. **(E)** Semiquantitative analysis of GPX4 and
 134 0.05, $**P < 0.01$, $***P < 0.001$. **(E)** Semiquantitative analysis of GPX4 and
 135 HSC70 expression in lysosomal and lysosomal free fractions from Figure 4D. $n = 3$, $*P < 0.05$. **(F, G)** Semiquantitative analysis of LAMP2A, ubiquitin, and
 136 = 3, $*P < 0.05$. **(F, G)** Semiquantitative analysis of LAMP2A, ubiquitin, and
 137 HSC70 from Figure 4G (F), as well as the expression of HA-ubiquitin and
 138 HSC70 in the IP fraction from Figure 4H (G). $n = 3$. $*P < 0.05$.
 139



140
 141 **Supplementary Figure S7 Semi-quantitative analysis of protein changes**
 142 **in GK induced K48-linked ubiquitination, lysosome translocation and**
 143 **degradation of GPX4 both in A549 and TFEB knockout A549 cells.**

144 **(A, B)** Semiquantitative analysis of GPX4 from Figure 5A (A), as well as the

145 expression of GPX4 from Figure 5B (B). (C) Semiquantitative analysis of GPX4
 146 both in lysosome and lysosome free fraction from Figure 5C (C). (D, E)
 147 Semiquantitative analysis of K48-linked polyubiquitin and LAMP2A in IP fraction
 148 from Figure 5F (D), as well as the expression of HA-K48-linked ubiquitin in IP
 149 fraction from Figure 5G (E). $n = 3$. * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$.
 150




151

152 **Supplementary Figure S8 Semi-quantitative analysis of protein changes**
 153 **in GK induced increase on the binding of GPX4 and TRIM25 both in A549**
 154 **and TFEB knockout A549 cells.**

155 (A) GPX4 stable transfection cells were treated or untreated with GK for 24 h.

156 Following treatment, cells were lysed, and immunoprecipitation was performed.
 157 The precipitates were analyzed using LC-MS. TRIM25 and UPS5 are most
 158 abundant E3 and DUBs in precipitants respectively. **(B, E)** Semiquantitative
 159 analysis of TRIM25 and USP5 expression in IP fraction from Figure 6A (B) and
 160 Figure 6D (E). **(C)** Semiquantitative analysis of TRIM25 both in IP and input
 161 fractions from Figure 6B. **(D)** Semiquantitative analysis of GPX4 from Figure
 162 6C. **(F)** Semiquantitative analysis of TRIM25 and USP5 expression in the IP
 163 fraction of A549 and TFEB knockout A549 cells from Figure 6E. $n = 3$, $*P < 0.05$,
 164 $**P < 0.01$, $***P < 0.001$.




165

166 **Supplementary Figure S9 GK induced ferroptosis is compromised by**
 167 **GPX4 overexpression**

168 **(A)** A549 cells were treated with LDC7559 (5 μ M), or Necrostatin-1 (10 μ M), or
 169 TEPA (1 mM) for 1h, then treated with GK for another 48 h. Cell viability was
 170 detected by CCK-8 assay. $n = 5$. **(B)** A549 cells were transfected with 3×flag-
 171 GPX4 or mock transfected with pcDNA3.1, then treated with GK for 24 h, cell
 172 viability was detected by MTT assay. $n = 5$. **(C)** The transfection and drug
 173 treatment were same as in (B). The cells were collected and stained with

174 BODIPY™ 581/591 C11 (10 μM) for 30 min. The level of lipid peroxidation was
 175 observed by flow cytometry ($\lambda_{exc} = 488 \text{ nm}$), 10,000 cells for each sample were
 176 analyzed. $n = 4$. **(D)** The transfection and drug treatment were same as in **(B)**.
 177 Then the cells were stained with CA-AM (0.5 μM), followed by iron chelator
 178 deferiprone (DFP, 100 μM) for 1 h or left untreated. The level of LIP was
 179 detected by flow cytometry ($\lambda_{exc} = 488 \text{ nm}$), 10,000 cells for each sample were
 180 analyzed. $n = 3$. **** $P < 0.0001$.
 181



182
 183 **Supplementary Figure S10 GK promote ferroptosis in LCC cells, and the**
 184 **changes of ferroptosis related protein in GK treated LUAD cells.**

185 **(A)** Semiquantitative analysis of GPX4, SLC7A11 and FTH in GK treated LUAD
 186 cells from Figure 7B. $n = 3$, * $P < 0.05$, ** $P < 0.01$. **(B)** LCC cells (NCI-H460)

187 were treated with GK (15 μ M) for 48 h in the presence and absence of
188 Ferrostatin-1 or lipoxstatin-1. The proliferation inhibition of the cells was
189 observed by MTT assay. $n = 4$, $*P < 0.05$, $**P < 0.01$, $****P < 0.0001$. **(C)** LCC
190 cells (NCI-H460) were treated with GK (15 μ M) for 6, 12, 24, 48 h. The protein
191 levels of SLC7A11, GPX4, and FTH were observed by western blot. β -actin
192 serves as internal control. **(D)** Semiquantitative analysis of GPX4, SLC7A11
193 and FTH from (C). $n = 3$, $*P < 0.05$, $**P < 0.01$. **(E-F)** LCC cells (NCI-H460)
194 were treated with GK (15 μ M) for 24 h, CA-AM was added to cells at the final
195 concentration of 0.5 μ M, followed by adding iron chelator deferiprone (DFP, 100
196 μ M) for 1 h or left untreated. The level of LIP was detected by flow cytometry
197 ($\lambda_{exc} = 488$ nm) (E). LCC cells (NCI-H460) were treated with GK (15 μ M) for
198 24, 48 h. The cells were collected and stained with BODIPY™ 581/591 C11 for
199 30 min. The level of lipid peroxidation was observed by flow cytometry ($\lambda_{exc} =$
200 488 nm) (F). 10,000 cells for each sample were analyzed. Up panel: The
201 fluorescence intensity of the cells was displayed in histograms. Lower panel:
202 The relative changes in Δ MFI (E) or mean fluorescence intensity (MFI) (F)
203 compared to the control group. $n = 3$, $***P < 0.001$, $****P < 0.0001$.